Autonomix Medical (AMIX) said Friday that it finalized the design of its Application Specific Integrated Circuits, or ASIC, microchip for its sensing technology catheter, following successful in vivo preclinical and bench testing.

This marks a key step toward the pivotal clinical trial of the device in the US, planned for 2025, according to the company.

The ASIC microchip is designed to facilitate nerve signal detection through vascular pathways, the company added.

Achieving this technical milestone should pave the way for commercialization of the company's Autonomix Sensing and RF Ablation System in the US as a treatment for pancreatic cancer pain, it said.

Shares of Autonomix Medical were up 8.5% in recent trading.

Price: 3.10, Change: +0.24, Percent Change: +8.53